Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Entrada Therapeutics, Inc.NASDAQ: TRDA
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns positive
Q1 FY2026 accounts payables was $641K, compared with -$1.91M a year earlier. Trailing-twelve-month accounts payables was $752K.
Context
- Accounts payables amounted to 7.1% of revenue in FY2025, up 6.6 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near $641K or moves back toward the trailing-twelve-month quarterly average of $188K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (1.8M) USD
- Year-over-year change
- -281.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.8M) | -281.5% |
| FY2024 | 2024-12-31 | 991K | +135.3% |
| FY2023 | 2023-12-31 | (2.81M) | -153.1% |
| FY2022 | 2022-12-31 | 5.29M | +839.4% |
| FY2021 | 2021-12-31 | (715K) | — |
Accounts Payables vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's LTM Mar 2026 accounts payables of $752K is the 6th largest of the 11 companies compared; the peer median is $44.5K.
- Its year-over-year change of +384.8% is the highest of 11, against a peer median of +31.3%.
- Accounts payables amounts to 13.1% of revenue for TRDA, versus a peer median of 3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.66M | +88.8% | +10.3% | 5.4% | |
| LTM Mar 2026 | $2.19M | -26.1% | -1.7% | 4.8% | |
| LTM Mar 2026 | $2.06M | +115.0% | — | — | |
| LTM Mar 2026 | $1.59M | -99.4% | +70.5% | — | |
| LTM Mar 2026 | $824K | -164.2% | — | — | |
| LTM Mar 2026 | $752K | +384.8% | — | 13.1% | |
| LTM Mar 2026 | $232K | -67.8% | — | — | |
| LTM Mar 2026 | $197.49K | +121.5% | — | — | |
| LTM Mar 2026 | $89K | +101.8% | -20.1% | 0.2% | |
| LTM Mar 2026 | $42K | -102.6% | — | 2.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | +100.0% | — | — |
| Peer median (excluding TRDA) | $44.5K | +31.3% | +4.3% | 3.5% | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.16M) | (94.62M) | (6.69M) | 65.63M | (143.75M) |
| Depreciation & Amortization | 1.12M | 1.9M | 2.84M | 3.77M | 4.1M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.53M | 9.9M | 13.11M | 17.92M | 19.61M |
| Change in Working Capital | (3.42M) | (11.11M) | 136.32M | (118.85M) | (4.8M) |
| Accounts Receivables | 0 | 0 | 0 | 2.2M | 2.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (715K) | 5.29M | (2.81M) | 991K | (1.8M) |
| Other Working Capital | (2.71M) | (16.4M) | 139.12M | (122.04M) | (5.5M) |
| Other Non-Cash Items | 74K | 151K | (5.78M) | (10.02M) | (3.67M) |
| Operating Cash Flow | (50.86M) | (93.79M) | 139.8M | (41.56M) | (128.51M) |
| Capital Expenditures | (4.58M) | (2.89M) | (5.61M) | (3.16M) | (1.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (221.98M) | (407.21M) | (437.72M) | (141.61M) |
| Sales of Investments | 0 | 76.21M | 274.43M | 413.08M | 259.46M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (4.58M) | (148.65M) | (138.4M) | (27.8M) | 116.81M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 190.69M | 479K | 19.41M | 99.61M | 887K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 939K | 0 | 1.63M | 3.36M | 0 |
| Financing Cash Flow | 307.46M | 479K | 21.04M | 102.96M | 887K |
| Effect of Forex Changes | 0 | (3.95M) | 0 | 0 | 0 |
| Net Change in Cash | 252.02M | (245.91M) | 22.45M | 33.61M | (10.82M) |
| Free Cash Flow | (55.44M) | (96.67M) | 134.19M | (44.72M) | (129.55M) |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.